MedPath

Evaluating the Efficacy and Safety of Vortioxetine vs. Escitalopram in Treating Depressive Disorder: A Comparative Study

Phase 4
Conditions
Health Condition 1: F321- Major depressive disorder, singleepisode, moderate
Registration Number
CTRI/2024/06/068969
Lead Sponsor
Himshikha Srivastava
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Both male and female patients aged between 18 and 60 years.

2. Those giving written consent/guardians giving written consent (in cases where the patients were too ill to understand the process of informed consent and give an informed choice.)

3. People diagnosed with the depressive disorder as per ICD-11 diagnostic criteria.

Exclusion Criteria

1. Systemic or Neurological Disorder affecting Cognition, Behavior or Mental Status.

2. Substance dependence except for Nicotine and Caffeine within the past month of entering the study.

3. Long-standing medical or surgical illnesses.

4. Patients with mental retardation or organic brain disorders.

5. Patients suffering from neurological, metabolic and vascular conditions affecting sexual function.

6. Patients with sexual dysfunction at baseline were excluded from the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath